In conclusion, 120 patients with T1DM included in this systematic review were C-peptide-positive, and the increase in the fasting C-peptide level, which was measured as an indicator of β-cell function, could not be confirmed in the group treated with DPP-4 inhibitors. The gene discussed is DPP4; the disease is type 1 diabetes mellitus.